Essex Bio-Technology Adds 18,000 Treasury Shares after HK$35.85 Thousand Buyback

Bulletin Express11-04

Essex Bio-Technology Limited executed an on-market repurchase of 18,000 ordinary shares on 4 November 2026, paying a total consideration of HK$35.85 thousand at prices ranging from HK$1.99 to HK$1.995 per share. The volume-weighted average repurchase price was approximately HK$1.9914.

Following the transaction, the company’s issued share capital (excluding treasury shares) decreased marginally from 564.70 million to 564.69 million, representing a 0.0032% reduction. Treasury shares rose to 2.32 million, keeping total shares in issue unchanged at 567.01 million.

Since the current share-buyback mandate was approved on 26 May 2026, Essex Bio-Technology has repurchased 2.32 million shares—equivalent to 0.41% of the shares outstanding on the mandate date—against an authorised ceiling of 56.70 million shares.

Under Hong Kong Stock Exchange rules, the company is subject to a 30-day moratorium on issuing new shares or disposing of treasury shares, effective until 4 December 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment